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ABSTRACT 
Nausea and vomiting was the frequently side effects in chemotherapy.Uncontrolled nausea and 
vomiting can cause weakened body condition, reduced appetite and drinking, dehydration, electrolyte 
disturbances, reduced nutritional status so the patient refused to undergo further chemotherapy. Anxiety is 
one of the factors that increase the risk of nausea and vomiting. We reported the case of the woman 48 
years old, height 150 cm, weight 51 kg, occupation housewife, diagnosed non-keratinizing squamous cell 
carcinoma cervical cancer  stage-IIB and received paclitaxel carboplatin for three cycles of chemotherapy. 
She experienced anxiety, acute nausea vomiting on the third cycle of chemotherapy and delayed nausea 
and vomiting of the three cycles of chemotherapy. 
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INTRUDUCTION  
Cervical cancer is a cancer that occurs in the area 
of the cervix.
1
 Chemotherapy is the treatment of 
cervical cancer stage IIB to stage IIIB using drugs either 
in the singular or combination.  
Paclitaxel carboplatin is one of the drugs used for 
chemotherapy of cervical cancer.
2 
Paclitaxel 
carboplatin resulted in a clinical response more than 
80% with a lower level of toxicity.
3 
In addition to providing a therapeutic effect, 
paclitaxel carboplatin can also cause various side 
effects. Nausea and vomiting are common side effects 
of chemotherapy.
4 
Uncontrolled nausea and vomiting 
can cause weakened body condition, reduced appetite 
and drinking, dehydration, electrolyte disturbances, 
reduced nutritional status so the patient refused to 
undergo further chemotherapy.
5 
Of the few studies, 
anxiety is one of the factors can increase the risk of 
nausea and vomiting. 
 
THE CASE  
A woman 48 years old, height 150 cm, weight of  
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51 kg, occupation housewife referred to polyclinic 
obstetrics and gynecology Sanglah Central Public 
Hospital Denpasar with complaints of abnormal 
bleeding, pain, weakness and lethargy.  
Cervical biopsy results showed that patients 
diagnosed with cervical cancer non-keratinizing 
squamous cell carcinoma stage IIB. Based on 
hematological examination and judgment of 
physicians, patients received chemotherapy with 
paclitaxel carboplatin. 
The first day, the patient was given combination 
of antiemetic such as dexamethasone 20 mg 
intravenously (iv), diphenhydramine 50 mg iv, 
ranitidine 50 mg iv were administered 30 minutes 
before paclitaxel 240 mg iv. After 24 hours of 
paclitaxel administered, patient rehydrated with 
dextrose 5% 500 cc for 5 hours. The second day, the 
patient was given combination of antiemetic: 
ondansetron 8 mg iv, vitamin B6 200 mg IV 30 were 
administered 30 minutes beforecarboplatin 600 mg iv. 
After 3 hours of paclitaxel administered, patient 
rehydrated with dextrose 5% 500 cc for 5 hours. On 
the third day, the patient is given medication to take 
home such as ondansetron 4 mg orally every 8 hours 
and ferrous sulfate 200 mg orally every 12 hours for 5 
days. This therapy was given for each cycle of the 
chemotherapy until the third cycle of chemotherapy. 
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Conditions and complaints of the patient monitored 
from the first cycle of chemotherapy until the third 
cycle. 
In the first cycle of chemotherapy in hospital, no 
experienced of nausea and vomiting and only 
complained of pain in the lower abdomen. However, 
after arriving at her home, she experienced delayed 
nausea and vomiting for 4 days.  
Three weeks after of the first cycle 
chemotherapy, the patient came to undergo a second 
cycle of chemotherapy and no experienced of nausea 
and vomiting.Same as the first cycle, she experienced 
delayed nausea and vomiting when she went home 
from the hospital for 3 days. 
She came back to the hospital for followed the 
third cycle chemotherapy. In the third cycle of 
chemotherapy, she started uneasy, anxiety and 
depression during hospitalization. She experienced 
acute nausea and vomiting that causes a decreased in 
appetite, changes in eating habits. She also 
experienced delayed nausea and vomiting while at 
home for 4 days. 
 
DISCUSSION (478 words) 
Nausea and vomiting is a common side effect in 
chemotherapy. Chemotheraphy induced nausea and 
vomiting (CINV) classified into acute, delayed, 
anticipatory, breakthrough. Acute CINV occurs less 
than 24 hours after chemotherapy. Delayed CINV is 
defined as nausea and vomiting occurring 24 hours or 
more after chemotherapy. Anticipatory CINV is 
defined as nausea and vomiting occurring before the 
administration of chemotherapy. Breakthrough  CINV 
is nausea and vomiting that occurs despite antiemetic 
therapy and requires rescue medication.
6,7 
In this case the patient no experienced nausea 
and vomiting during chemotherapy in a hospital in 
cycles 1 and 2. The combination of antiemetics such as 
diphenhydramine, ranitidine, dexamethasone, 
ondansetron, vitamin B6 given before chemotherapy to 
control the incidence of nausea and vomiting.
8,9,10 
However, patient’s experience delayed nausea and 
vomiting when at home and can be treated by oral 
ondansetron  taken home. Ondansetron is an 
antiemetic class 5HT3 receptor antagonist that is 
effective in treating nausea and vomiting.
12 
The 
mechanism of action of ondansetron is selectively 
inhibit 5-hydroxytriptamine (5HT3) receptor in the CTZ 
(Chemoreceptor Trigger Zone) and in the 
gastrointestinal tract. 
In the third cycle of chemotherapy, although 
patients given the combination antiemetic before 
chemotherapy, the patients continue to experienced 
acute nausea and vomiting. Several factors are known 
to increase the incidence of nausea and vomiting were 
age, anxiety, history of motion sickness, morning 
sickness history, consume less alcohol.
11,12,13 
Anxiety is one of the factors that are important 
to trigger nausea and vomiting. This can be explained 
by the following scheme: 
 
Figure 1 
The cascade of anxiety induced nausea and vomiting
11
 
 
Emotional distress symptom and  multiple 
receptors in the cerebral cortex responsible the 
occurrence of nausea and vomiting (figure 1). Signals 
from the cerebral cortex then relayed to the vomiting 
center (nucleus tractus solitaries) and stimulate  
salivary and respiratory centers, reverseperistaltic of 
the stomach, twiching of the diaphragm and 
abdominal musclesso that the occurrence of 
vomiting.
14,15
 
In this case, the patient experience anxiety when 
will undergoing the third cycle of chemotherapy 
thereby increasing the incidence of nausea and 
vomiting. Some triggers of anxiety in these patients 
such as the severity of disease experienced, the 
influence of other patients who experience nausea 
and vomiting, uncontrolled pain, chemotherapy 
agents. Several studies have reported that the severity 
of disease experienced, confidence in adapting from 
environmental influences, uncontrolled pain, 
chemotherapy agents is the trigger anxiety during 
chemotherapy.
17,18 
Therefore, further anxiety 
treatments are needed to reduce the risk of nausea 
and vomiting during chemotherapy. 
After the third cycle of chemotherapy in the 
hospital completed, the patient experienced delayed 
nausea and vomiting at her home. Ondansetron was 
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given at home and taken for 5 days to treat nausea 
and vomiting delayed. 
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